期刊文献+

小剂量白介素2治疗风湿免疫疾病的研究进展

Research progress in the treatment of rheumatic immune diseases with low-dose interleukin-2
下载PDF
导出
摘要 效应T细胞和调节性T(Treg)细胞之间的紊乱是风湿免疫疾病的重要发病机制,故也是风湿免疫疾病治疗的一个关键环节。白介素2(IL-2)可以有效地促进、改善Treg细胞的分化、增殖,从而达到恢复免疫平衡的目的。现已有大量研究表明了IL-2治疗各类风湿免疫疾病的有效性及安全性,本文将对IL-2在风湿免疫疾病中的作用进行综述。 The disorder between effector T cells and regulatory T(Treg)cells is an important pathogenesis of rheumatic immune diseases,so it is also a key link in the treatment of rheumatic immune diseases.Interleukin-2(IL-2)can effectively promote and improve the differentiation and proliferation of Treg cells,thus achieving the purpose of restoring immune balance.At present,a large number of studies have shown the efficacy and safety of IL-2 in the treatment of various rheumatic immune diseases.This paper will review the role of IL-2 in rheumatic immune diseases.
作者 曹继元 吴金玉 黄志敏 CAO Jiyuan;WU Jinyu;HUANG Zhimin(Graduate School of Guangxi University of Traditional Chinese Medicine,Nanning,Guangxi 530001,China;Department of Rheumatology,First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine,Nanning,Guangxi 530023,China)
出处 《医药前沿》 2023年第10期50-53,共4页 Journal of Frontiers of Medicine
基金 广西中医药大学硕士研究生创新课题(YCBXJ2021007)。
关键词 白介素2 调节性T细胞 风湿免疫疾病 Interleukin 2 Regulatory T cell Rheumatic immune disease
  • 相关文献

参考文献3

二级参考文献16

  • 1Van der Linden S,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis and Rheumatism . 1984
  • 2Y. Shinohara,Y. Ezura,H. Iwasaki,I. Nakazawa,R. Ishida,M. Kodaira,M. Kajita,T. Shiba,M. Emi.Linkage disequilibrium and haplotype analysis among ten single-nucleotide polymorphisms of interleukin 11 identified by sequencing of the gene[J]. Journal of Human Genetics . 2001 (8)
  • 3Cho N,Nguyen DH,Satkunendrarajah K,et al.Evaluating the role ofIL-11,a novel cytokine in the IL-6 family,in a mouse model ofspinal cord injury. J Neuroinflammation . 2012
  • 4Braun J,,Sieper J.Ankylosing spondylitis. The Lancet . 2007
  • 5Brown MA,Laval SH,Brophy S,et al.Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases . 2000
  • 6Ottaviani S,Allanore Y,Tubach F,Forien M,Gardette A,Pasquet B,Palazzo E,Meunier M,Hayem G,Job-Deslandre C,Kahan A,Meyer O,Dieudé P.Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Research and Therapy . 2012
  • 7Sarholz M,Vorgerd M,Braun J.Camplocormia in the differential diagnosis of hyperkyphosis and ankylosing spondylitis. Deutsche Medizinische Wochenschrift . 2012
  • 8Kroon F,Landewe R,Dougados M,van der Heijde D.Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases . 2012
  • 9Liu Y,Gao X,Deeb D,Arbab AS,Dulchavsky SA,Gautam SC.Anticancer agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell proliferation. Journal of Experimental Therapeutics and Oncology . 2012
  • 10H(o|¨)fer T,Krichevsky O,Allan-Bonnet G.Competition for IL-2 between regulatory and effector T cells to Chisel immune responses. Front Immunol . 2012

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部